. DNA methylation occurs predominantly at palindromic CpG dinucleotides through the addition of a methyl group to the 5ʹ position of the cytosine pyrimidine ring, thereby generating 5-methylcytosine (5mC) ( Fig. 1a; Supplementary Fig. 1 ). It also occurs, albeit more rarely, in non-CpG sequences. Three enzymes, DNA methyltransferase 1 (DNMT1), DNMT3A and DNMT3B, methylate DNA and maintain genomic methylation patterns 2 . In what has been proposed to be the initial step of active DNA demethylation in mammals, the ten-eleven translocation (TET) dioxygenases oxidize the 5-methyl group of 5mC to produce 5-hydroxymethylcytosine (5hmC), 5-formylcytosine or 5-carboxylcytosine 6 ( Supplementary Fig. 1 ). More recently, N 6 -methyladenosine (m 6 A) was also identified in mammalian genomes, although its physiological roles remain unclear 7, 8 . A more detailed discussion of DNA methylation can be found in reF. 9 . Most of the known RNA modifications are methylations (more than 70 types of RNA methylation have so far been identified) but their molecular functions remain largely unknown (Fig. 1b) . Until recently, the vast majority of modifications had been ascribed only to ribosomal RNA and/or tRNAs owing to their cellular abundance. Pioneering research is now revealing that all RNA species are methylated (for examples, see reFs [10] [11] [12] [13] [14] ), and that demethylation at specific sites occurs, at least in the case of m 6 A (reFs 15, 16 ) ( Fig. 1c; Supplementary Fig. 1 ). Methylation of mRNA is an exciting and rapidly expanding field, which is reviewed in detail in reF. 17 . Protein methylation occurs mainly on the side chains of Lys and Arg residues, but methylation of other residues also occurs in mammals 18 . The major focus of this Review is methylation of histone residues (Fig. 1c) and primarily the involvement of Lys and Arg methy lation pathways in disease. Lys residues may be monomethylated, dimethylated or trimethylated (me1, me2 or me3, respectively), whereas Arg residues may be monomethylated or symmetrically or asymmetrically dimethylated (me1, me2s or me2as, respectively) 19 ( Supplementary Fig. 1 ). Unlike acetylation and phosphorylation, histone methylation does not alter the charge of the histone protein. The protein arginine N-methyltransferases (PRMTs) are structurally related, as are almost all histone lysine N-methyltransferases, which contain a conserved seT domain. One exception is DOT1L, which methylates histone H3 Lys79 (H3K79). A more detailed description of histone methylation can be found in Fig. 1c and reFs 19, 20 . During the methylation reaction, SAM is converted into S-adenosylhomocysteine (SAH), which inhibits methyltransferase activity 21 . Thus, methyltransferases are susceptible to changes in the cellular SAM-to-SAH ratio. Raising the cellular levels of SAM can repress proto-oncogenes through CpG methylation of their promoters 22 . Additional methylation complexity exists because certain enzymes methylate different classes of macromolecule. For example, human nucleolar protein 1 catalyses 2ʹ-O methylation of ribosomal RNA, as well as methylation of Gln105 of histone H2A 23 . DNMT2 is structurally related to the other DNMTs, yet it possesses only weak DNA methylation activity and catalyses 5mC in tRNA very efficiently 24 .
• TRMT10C (m • MLL1-4 DNMT1 preferentially methylates hemimethylated CpG sites (the existing methylation of one of the DNA strands is marked in light green) and maintains methylation following cell division, whereas DNMT3A and DNMT3B have equal preferences for unmethylated and hemimethylated sites and are therefore responsible for de novo methylation at unmethylated CpG sites. Methylation of adenine is shown although the enzyme responsible for the formation of 6-methyladenosine (m Until relatively recently, the methyl groups on DNA, RNA and proteins were generally considered to be highly stable modifications 25 . However, the identification of specific demethylases ( Fig. 1; Supplementary Fig. 1 ) has revealed that methylation is a dynamic process, which is consistent with its important regulatory roles 19 . As we discuss below, this dynamic nature provided the rationale for therapeutic intervention.
In this Review, we discuss the cellular functions of DNA, RNA and histone methylation, and their dynamics during normal ageing. We then focus on how mutations in the various writers, readers and erasers of chromatin methylation contribute to cancer and why drugs that alter their function may be important to treat various malignancies. Early clinical trial data for these drugs are beginning to emerge; we provide a perspective on these data and the key knowledge gained regarding the safety and efficacy of this exciting new class of drugs. Finally, we discuss promising strategies for monitoring dynamic changes in chromatin methylation for diagnostic and prognostic purposes and potential new avenues for manipulating chromatin methylation in combination with established anticancer drugs to improve the clinical utility of epigenetic therapies.
The cellular functions of methylation Important clues to the functions of particular DNA, RNA or histone methylation marks can be gained from knowledge of their cellular and intramolecular localizations. Thus, much effort has been expended in mapping the modified sites using various biochemical techniques (for example, chromatin immunoprecipitation assays) and biophysical techniques (for example, mass spectrometry), which together have provided detailed genomic and transcriptomic methylation profiles.
CpG DNA methylation is widespread in mammal ian genomes, with around 70% of CpG dinucleotides being methylated. The exception to this pattern is CpG-rich regions (known as CpG islands) within the promoters of active genes, which are characteristically unmethylated 26 ( Fig. 2a) . CpG DNA methylation is a fundamental mechanism of stable gene repression, which underlies processes such as X chromosome inactivation and gene imprinting 26 . CpG methylation is significantly enriched in heterochromatin and in many inactive gene promoters. Active genes can also harbour methyl ated CpGs within their transcribed regions, where they regulate mRNA alternative splicing by recruiting methyl-CpG-binding protein 2 (reF. 27 ). Notably, many tumour suppressor is low at promoter regions, whereas genic and intergenic regions are highly methylated 225 . Distal regulatory elements such as enhancers are commonly marked by low levels of 5mC and higher levels of its oxidation derivative 5-hydroxymethylcytidine (5hmC). Changes in enhancer methylation are associated with deregulation of large-scale chromatin organization into loops, which are normally maintained by binding of boundary factors such as CCCTC-binding factor (CTCF) and cohesin. In ageing and in cancer, a limited number of genomic loci gain DNA methylation, particularly at CpG islands in promoters of tumour suppressor genes (TSGs) 62 and of Polycomb-repressed genes 60, 61 (not shown), leading to gene silencing. In normal tissues, repetitive elements are maintained in heterochromatin and are highly methylated. Demethylation of retrotransposons and satellite repeats and high levels of their transcription are observed in ageing cells 52 and in human cancer [78] [79] [80] . b | Histone methylation. In cells in replicative senescence, a general loss of nucleosomes is observed (not shown) 75, 76 , and ageing cells have an altered chromatin composition, including high levels of the heterochromatin factors histone H2A variant macroH2A and heterochromatin-binding protein 1β (HP1β) 73, 74 . Some of these features are also seen in cancer cells, where they can promote gene silencing. In ageing cells, some active loci marked with trimethylated histone H3 Lys4 (H3K4me3) additionally gain the repressive modification H3K27me3, and are hence termed 'bivalent domains' 70, 71 . In normal cells, promoters in would-be bivalent loci have the lowest levels of DNA methylation 71 ; during ageing, these promoters undergo DNA hypermethylation 60 , which is also a key feature of several cancers [226] [227] [228] and may lead to reduced expression of TSGs. The strength and type of the arrows indicate the level of gene expression.
X chromosome inactivation
A gene-dosage compensation process by which one of the two X chromosomes in the cells of female mammals is transcriptionally silenced through heterochromatin formation.
Gene imprinting
Heritable gene expression pattern established in the germline through epigenetic modifications to maintain parent-of-origin gene-expression status in somatic cells.
genes are silenced by DNA methylation in cancer 26 . Furthermore, mammalian genomes consist mainly of repetitive elements, and many of them are methylated 28 . Hypomethylation of these repetitive elements is observed in cancer cells 29, 30 and can lead to activation and transposition of endogenous retroviral elements, thereby promoting genomic instability during early embryogenesis 31 and tumour development 1 (Fig. 2a) .
No strict rule governs the genomic distribution of methylation of different histone residues 19, 32 . In the loosely packed euchromatin, certain methylations, such as H3K4me3, are present in active promoters, whereas H3K36me3 is present within actively transcribed regions preferentially at exons, albeit at lower levels in alternatively spliced exons 33 . Other histone methylations, such as H3R17me2as, mark the promoters of active hormone-regulated genes. Active genes are also marked by methylated H3K79, but this methylation is also linked to many other processes, including the DNA damage response and heterochromatin formation (reviewed in reFs 34, 35 ). Specific functional regions in the genome, such as enhancers and origins of DNA replication, are also marked by specific histone methylations; in these cases H3K4me1 and H3K36me1, respectively. Histone methylation in the tightly packed heterochromatin depends on the subtype of heterochromatin: facultative or constitutive. Facultative heterochromatin contains genes that are differentially expressed during development and/or cell differentiation and which then become silenced. It is characterized by the gene-repressive modification H3K27me3, for example at the inactive X chromosome in mammalian female cells. By contrast, constitutive heterochromatin is particularly enriched with the repressive modifications H3K9me2 and H3K9me3 (reFs 19, 36 ). Finally, certain developmental genes possess so-called bivalent domains that contain both gene-active H3K4me3 and gene-inactive H3K27me3 modifications. This 'poised' state is thought to allow these genes to rapidly respond to differentiation cues 37 . Histone methylation predominantly functions by directly recruiting or inhibiting the recruitment of histone-binding proteins. For example, H3K4me3 specifically recruits activating proteins, including transcription factors to gene promoters, while inhibiting binding of transcription repressors such as the nucleosome remodelling and deacetylase complex 19, 32 . In mammalian heterochromatin, H3K9me2 and H3K9me3 are specifically bound by the chromodomain of the heterochromatin protein 1 (HP1) family, particularly HP1β, which is important for the formation of the higher-order architecture of heterochromatin 19, 32 (Fig. 2b) . Methylation such as that of H4K20 also underpins genomic integrity 38 .
Although it is clear that histone modifications robustly modulate key nuclear processes and there is strong evidence for the role of histone methylation in DNA-related processes, as outlined above, it is difficult to experimentally prove a direct causative role of any histone modification in mammalian cells (see reF.
39 for a discussion). This constraint is further compounded by most histone methyltransferases also methylating non-histone proteins, such as the tumour suppressor protein p53 (reF. 40 ), and by some methyltransferases methylating multiple types of macromolecule 23 , as described above. In the case of RNA methylation, the situation is even more confounded because methylation can occur post-transcriptionally 41 or co-transcriptionally 10 . Furthermore, unlike histone methylation, some RNA methylations directly affect local secondary structures. For example, m 7 G destabilizes G quadruplexes in precursor microRNAs to regulate their processing 42 . Other RNA methylations may act as binding platforms for specific RNA-binding proteins, as exemplified by m 6 A, which is bound by YTH-domain proteins 43 . Overall, RNA methylation can directly affect RNA processing, stability, translation and localization 44 . The effect may even be trans acting, as exemplified by m 6 A in the long non-coding RNA X-inactive specific transcript (XIST), which is required for transcriptional repression of the inactive X chromosome by XIST 45 . Thus, methylation is widespread throughout the genome and epitranscriptome, which creates many opportunities for crosstalk between different methylation pathways. This is exemplified in histones, where crosstalk occurs not only between methylations within the same histone protein but also between modifications in different histones (reviewed in reFs 19, 32 ). There can also be cooperation between methylation of histones and methylation of DNA. For example, the RING E3 ubiquitin ligase UHRF1 binds to nucleosomes containing H3K9me3, and this is significantly enhanced by CpG methylation of the nucleosomal DNA 46 . Furthermore, the ubiquitin-like domain of UHRF1 promotes ubiquitylation of histone H3, which recruits DNMT1 to newly replicated chromatin to ensure the methylation of the DNA 47 
.
As discussed above, distinct methylation patterns are found in heterochromatin and euchromatin regions. There are well-defined regions of demarcation -'bound ary elements' -between heterochromatin and euchromatin and between topologically associating domains. CCCTC-binding factor (CTCF), which has an important role in maintaining boundaries between these types of genomic domains, binds to DNA in a methylationdependent manner 48, 49 . CpG methylation prevents CTCF binding, suggesting a role for DNA methylation in establishing and/or maintaining higher-order topological structures of the genome.
Methylation in ageing and cancer
Although the primary focus of this Review is the role of chromatin methylation in cancer, it is important to emphasize that methylation of DNA, RNA and histones has also been widely implicated in developmental diseases, non-malignant acquired diseases such as autoimmunity, and ageing. Generally, the methylation pathways and the DNA-related processes they regulate are highly conserved in mammals. The importance of chromatin methylation is further underscored by the fact that disruption of these processes, through inherited or acquired mutations in their main factors, results in embryonic lethality or can produce severe diseases [1] [2] [3] [4] [5] . As a cell ages, its DNA and histone methylation landscapes change. Early studies suggested that global DNA hypomethylation is a hallmark of ageing; however, recent work has shown that loss of DNA methy lation occurs primarily in constitutive-heterochromatin repeat regions, while hypermethylation primarily occurs at promoter CpGs 50, 51 (Fig. 2) . As discussed earlier, in normal tissues repetitive elements are highly methylated to prevent their transcription. Ageing is accompanied by selective loss and reorganization of heterochromatin and upregulation of transcripts from repeat elements, in particular retrotransposable elements 52 , the genomic transposition of which is associated with the formation of DNA double-strand breaks 53, 54 and can negatively impact genome stability and cause disease 55 . By contrast, a stable epigenome is reported to contribute to longevity and cancer resistance 56 . Increased locus-specific DNA hypermethy lation has been reported in ageing blood and tissues 57, 58 and appears to be conserved between mice, monkeys and humans 59 . DNA methylation tends to increase with age at some CpG islands, particularly at Polycomb target genes 60, 61 and at promoters of tumour suppressor genes 62 ( Fig. 2a) . The sum of these changes in DNA methy lation likely establishes an age-related transcriptional programme 58 . In line with this, a number of DNA methylation 'clocks' have been described (discussed in reF. 63 ): genome-wide DNA methylation can serve as a reliable estimator of age 64 and predict mortality 65 and lifespan 66, 67 in model organisms. Age-associated changes in histone methylation are also context specific, and conflicting data from different ageing models exist 68, 69 . A gain of novel bivalent domains is observed in ageing cells 70, 71 , and increased levels of heterochromatin-associated proteins, such as the histone H2A variant macroH2A, which is associated with gene repression, 72 and HP1β, were observed in tissues from old versus young mice and primates 73, 74 ( Fig. 2b) . A general loss of histones and redistribution of methylation modifications has also been observed in yeast and in human fibroblasts 75, 76 , suggesting that this is an evolutionarily conserved mechanism that regulates replicative lifespan, but it remains unclear whether replicative senescence also occurs in mammalian cells in vivo.
In addition to changes in DNA and histone methylation, certain mRNAs have fewer m 6 As in old human blood cells than in young blood cells 77 . Thus, biological methylation exists in flux, responding to various diseases and natural processes such as ageing. It is the existence of such dynamic equilibria that underpins the rationale to therapeutically target these methylation pathways in the hope that pathological perturbation of the methylome can be reversed.
Age-associated co-morbidities, one of the best studied of which is cancer, ultimately shorten lifespan. The same changes documented in ageing cells, such as demethylation of retrotransposons and satellite repeats and a considerable increase in their transcription, are also observed in human cancers [78] [79] [80] . In recent years, we have begun to gain fascinating insights into the origins of cancers, which are derived from clonal populations of cells bearing deregulated chromatin. An excellent example of this is age-related clonal haematopoiesis (ARCH) 66 . In more than 10% of adults aged 60 years or older, steady-state haematopoiesis (more than 5 × 10 11 blood cells are generated each day) occurs from a restricted number of clonal haematopoietic stem cells and progenitor cells that harbour somatic mutations that confer a clonal advantage. Strikingly, ARCH is associated with an increased risk of a subsequent haematological malignancy and with an almost twofold increased risk of cardiovascular death [81] [82] [83] . Mutations in the genes encoding DNMT3A, TET2 (Supplementary Table 1) and ASXL1, which regulate DNA and histone methy lation, account for more than 70% of cases of ARCH [81] [82] [83] . Remarkably, these findings in patients 84 could have been largely predicted from mouse models in which these genes have been conditionally deleted in haematopoietic tissues. Haematopoietic stem cells from these mice show an increased self-renewal capacity, allowing them to outcompete non-mutated haematopoietic stem cells and clonally expand [85] [86] [87] [88] [89] [90] . The prognostic significance of diseases such as acute myeloid leukaemia (AML), which is sometimes preceded by pre-existing ARCH, is yet to be fully determined. However, the presence of clonal haematopoiesis was reported to negatively affect clinical outcomes in patients receiving treatment for non-haematological cancers 91 . Clonal haematopoiesis does not just influence cancer development and therapeutic responses but is also a major risk factor for atherosclerotic disease, which is another feature of ageing 92, 93 . There remains much to be learnt about the global changes in chromatin methylation in conditions such as ARCH, and how this may influence the development of cancer and cardiovascular disease. While there is compelling evidence correlating ARCH with a range of diseases frequently observed in advanced age, if we are to develop strategies to alter this process it is imperative that we understand the molecular causes behind these associations.
Methylation deregulation in cancer
Global and local changes to DNA and histone methylation are a seminal feature of cancer cells (Fig. 2) . A major finding from genomic studies such as The Cancer Genome Atlas programme has been that pervasive mutations occur in a range of enzymes that methylate and demethylate DNA and histones 1, 94 . The diverse range of mole cular mechanisms used by cancer cells to alter chromatin methylation patterns was relatively unexpected. These mechanisms include mutations in metabolic enzymes, which result in the production of oncometabolites that essentially poison the iron-dependent dioxygenases that regulate histone and DNA demethylation, and somatic mutations in core histone genes that lead to a global loss of the histone modifications (Fig. 3) .
d-2-Hydroxyglutarate (D2HG) is an oncometabolite that inhibits numerous demethylases, leading to changes in genomic and transcriptomic methylation profiles and to changes in gene expression and genome topo logy 36, [95] [96] [97] . Oncogenesis has been associated with specific mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) and IDH2, which prevent the conversion of isocitrate into α-ketoglutarate and additionally
Replicative lifespan
The time during which a cell can divide and produce daughter cells before becoming senescent.
Oncometabolites
Metabolic intermediates that accumulate in cancer cells, often through loss-of-function or gain-of-function mutations in genes that encode enzymes, resulting in cancer-relevant epigenetic changes.
promote the reduction of α-ketoglutarate to its structural analogue D2HG 98, 99 . The TET family of proteins involved in DNA demethylation and the Jumonji C domain family of histone demethylases are examples of iron-dependent dioxygenases whose catalytic activity at chromatin is competitively inhibited by elevated levels of D2HG (Fig. 3a) . Mutations in IDH1 and IDH2 are mutually exclusive in AML, where they induce cytosine hypermethylation and inhibit TET2-mediated 5-hydroxymethylation 100, 101 . This results in aberrant DNA cytosine methylation (5mC and 5hmC) patterns, including hypermethylation at genes involved in proliferation and differentiation, and gains of histone methylation. The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 100, 102 . This is supported by the overlap of DNA methylation profiles of TET2-mutant AML with those of IDH1-mutant and IDH2-mutant cancers.
In addition to TET enzymes, D2HG can inhibit α-ketoglutarate-dependent dioxygenase FTO, which demethylates m 6 A RNA 16 . This leads to considerably higher m 6 A levels in IDH1-mutant and IDH2-mutant AML than in IDH1 and IDH2 wild type AML, despite comparable FTO expression levels 95 . Although evidence points to an oncogenic role of FTO in AML 16 , a recent study suggested that inhibition of FTO by accumulated D2HG may have opposing, pro-tumour and antitumour effects in both AML and glioma, depending on the mutation status of IDH and the abundance of FTO and MYC 103 . Deconvoluting the contribution of each enzyme affected by D2HG and understanding what roles the observed changes in DNA and histone methylation have in initiating and maintaining these malignancies is the subject of ongoing research and is likely to influence future therapeutic decisions.
One of the best examples of deregulated histone methylation resulting in changes in gene expression and genome integrity is the extensive loss and gain of H3K27me3. This can occur through various mechanisms, including recurrent gain-of-function or loss-offunction mutations in the gene that encodes enhancer of zeste homologue 2 (EZH2), which is the primary methyltransferase responsible for this histone modification 104 . More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by 'oncohistones' 105 ( Fig. 3b) , which are mutant histones with oncogenic features. Around 30% of all paediatric glioblastomas contain mutations in histone genes, which result in amino acid substitutions at or near key sites of regulatory modifications in the histone tails, suggesting that they might disrupt the reading, , and result in the expression of oncohistones and change of DNA and histone methylation patterns (bottom; increases and decreases of methylation are indicated by arrows pointing up and down, respectively). H3K27M and H3G34R mutations are two such examples. Histone H3 Lys27 to Met substitution (H3K27M) leads to inhibition of Polycomb repressive complex 2 (PRC2), and there is evidence that methylation of histone H3 Lys36 (K36) by histone-lysine N-methyltransferase SETD2 is inhibited by H3G34R 230 . Glioblastomas with H3.1K27M, H3.3K27M or H3G34R mutations are found in distinct parts of the brain (indicated by the colour-matching circles), suggesting they arise from differences in the cell of origin or in the tumour environment.
writing and/or erasing of these modifications. These oncohistone mutations include H3K27M, H3K27I, H3G34V and H3G34R (reviewed in reF. 105 ). Of these, up to 90% of diffuse intrinsic pontine gliomas harbour the K27M point mutation in the gene that encodes canonical histone H3.1 (HIST1H3B) or in the gene that encodes variant histone H3.3 (H3F3A) [106] [107] [108] . Like other oncohistone mutations 109 , they are maintained throughout the course of the disease, suggesting that they are driver mutations and are required for tumour maintenance 110 . H3K27M mutations in HIST1H3B or H3F3A are mutually exclusive with each other and with Gly34 to Arg or Val substitutions (H3.3G34R or H3.3G34V, respectively). Although these tumours are histologically indistinguishable, the different histone mutations mark a clinically and epigenetically distinct group of glioblastomas. The H3.3G34V or H3.3G34R mutated tumours are found almost exclusively in the cerebral hemispheres 106, 107 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 111 ( Fig. 3b ). This striking anatomical restriction is currently unexplained and potentially suggests distinct cells of origin or a cell-extrinsic factor, such as the surrounding tumour microenvironment that considerably influences the anatomical tropism of these genetically distinct tumours.
The different mutations promote similar global histone modification changes, most notably loss of H3K27me2 and H3K27me3, leading to derepression of genes, or redistribution of the active mark H3K36me3, together with general DNA hypomethylation (Fig. 3b) . Global H3K27me3 loss in H3K27M diffuse intrinsic pontine gliomas was initially proposed to be due to inactivation of Polycomb repressive complex 2 (PRC2), the H3K27me3-catalysing subunit of which is EZH2, through sequestration of EZH2 to H3K27M 112 . Despite reports supporting a higher affinity of PRC2 for H3K27M compared with wild type H3 (reFs [113] [114] [115] ), H3K27M is often inversely correlated with PRC2 occupancy, thereby challenging the idea that H3K27M sequesters PRC2 on chromatin 116, 117 . A new model, which proposes a dynamic hit-and-run PRC2-H3K27M interaction, may reconcile some of these findings 118 . Several studies have shown that the loss of H3K27me3 (for example, through H3K27M) leads to major gene expression changes that are accompanied by a concomitant gain of acetylation at H3K27 (reFs 112, 116, 119 ). These findings have encouraged exploration of the possibility that epigenetic therapies may reset the imbalance caused by the oncohistones [120] [121] [122] [123] [124] . Despite these advances, we are still at the early stages of our understanding of the molecular mechanisms by which oncohistones contribute to the formation of these anatomically distinct malignancies and how they may be therapeutically targeted.
Therapeutic targeting of methylation
The basis of targeting epigenetic regulators in cancer lies in manipulating the oncogenic transcriptional programme to modulate the expression of genes driving malignant progression; in essence, reprogramming cancer cells into a more 'normal' , differentiated state. An array of novel compounds targeting the enzymatic domains of chromatin methylation writers, erasers and readers have entered the preclinical and clinical arena in recent years 125 . Here we primarily focus on the first-in-class epigenetic therapies that have progressed to evaluation in clinical trials.
Inhibitors of DNA methyltransferases
Inhibitors of DNMTs in current clinical use, such as azacitidine (5ʹ-azacytidine) and decitabine (5-aza-2ʹ-deoxycytidine), are cytidine analogues that incorporate themselves into replicating DNA and covalently bind and sequester active DNMTs, thereby triggering their degradation by the proteasome. These inhibitors therefore have broad cellular effects owing to their indiscriminate inhibition of all DNMT-containing complexes, leading to global loss of DNA methylation 126 . Furthermore, incorporation of cytidine analogues into RNA and DNA induces DNA damage and inhibits protein synthesis, which causes cytotoxicity at high doses. Lower, subcytotoxic doses have received regulatory approval for the treatment of myelodysplastic syndrome (MDS) and AML as drugs with demonstrated efficacy for patients unfit for intensive chemotherapy [127] [128] [129] . The prolonged time to initial response, which typically occurs around 3 months from treatment onset 130 , is consistent with the primary effects of low-dose treatment being mediated through DNA demethylation and epigenetic reprogramming as opposed to direct cytotoxicity [131] [132] [133] . Although rates of response to azacytidine of up to 60% have been reported for MDS 130, 134 , DNMT inhibitors have shown limited clinical efficacy as monotherapy for solid tumours. This has been attributed to a number of factors, including limited incorporation into DNA as a consequence of slower cell proliferation in solid tumours, poor cellular uptake and meta bolic instability. This prompted the development of modified cytidine analogues with increased stability and oral bioavailability 134 . Several of these have shown efficacy in preclinical solid tumour models and are currently in clinical trials for a range of malignancies (TAble 1) . Despite their limitations, DNMT inhibitors are the most effective epigenetic therapy developed to date, and hopefully the development of specific catalytic inhibitors of individual DNMT enzymes, or targeting of specific DNMT-containing complexes, may yield more potent and specific antitumour effects while circumventing the dose-limiting toxic effects associated with cytidine analogues. To this end, a reversible, non-DNA-incorporating selective inhibitor of DNMT1 was recently developed and was shown to elicit global reduction in DNA methylation and to inhibit tumour growth in mouse models 135 .
Modulators of histone methylation
A large number of specific inhibitors of different histone methyltransferases have been developed over the past few years (reviewed in reFs 136, 137 ). Inhibitors of EZH2, DOT1L, PRMT1 and PRMT5 have now entered clinical trials, with clinical development being most advanced for inhibitors of EZH2. EZH2 inhibitors. EZH2 is the catalytic subunit of PRC2; other PRC2 subunits include suppressor of zeste 12 (SUZ12), embryonic ectoderm development protein (EED) and retinoblastoma-binding protein p46 (also known as RBBP7) 138 . EZH2 promotes gene silencing by catalysing monomethylation, dimethylation and trimethylation of H3K27 (reF. 104 ). The EZH2 homologue EZH1 possesses less-potent histone methyltransferase activity yet may still contribute to H3K27 methylation in specific contexts, particularly when EZH2 levels are low 139 . EZH2 is crucial for B cell maturation and is a promising therapeutic target in multiple myeloma, follicular lymphoma and diffuse large B cell lymphoma (DLBCL) 140 (TAble 1) . Around 20-30% of follicular lymphomas and germinal-centre DLBCLs harbour hetero zygous point mutations in specific residues in the EZH2 SET domain (Y641, A677, A687), which enhance targeting of dimethylated Trial information is taken from ClinicalTrials.gov. ALL , acute lymphoblastic leukaemia; AML , acute myeloid leukaemia; ATRA , all-trans retinoic acid; BAP1, BRCA1-associated protein 1; CMML , chronic myelomonocytic leukaemia; CRPC, castration-resistant prostate cancer ; CTL A4: cytotoxic T lymphocyte-associated protein 4; DLBCL , diffuse large B cell lymphoma; DNMT, DNA methyltransferase; DOT1L , disruptor of telomeric silencing 1-like protein; EED, embryonic ectoderm development protein; EZH2, enhancer of zeste homologue 2; HDAC, histone deacetylase; H3K27 , histone H3 Lys27; H3K79, histone H3 Lys79; IDO1, indoleamine 2,3-dioxygenase 1; LSD1, lysine-specific demethylase 1A ; MDS, myelodysplastic syndrome; NEDD8, neural precursor cell expressed developmentally downregulated 8; NSCLC, non-small-cell lung cancer ; PD1, programmed cell death protein 1; PDL1, programmed cell death 1 ligand 1; PRC2, Polycomb repressive complex 2; PRMT5, protein arginine methyltransferase 5; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; SCLC, small-cell lung cancer ; SMARCB1, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1; THU, tetrahydrouridine. and monomethylated over unmethylated H3K27, thereby leading to substantially increased levels of H3K27me3 (reFs [141] [142] [143] ). An acquired dependence on EZH2 activity is also seen in BRCA1-associated protein 1 (BAP1)-mutant malignant mesothelioma 144 and in tumours with defects in the chromatin remodelling complex SWI/SNF 145, 146 , for example, in malignant rhabdoid tumours deficient in the SWI/SNF subunit SMARCB1 (reF. 147 ).
The SWI/SNF nucleosome remodelling complex antagonizes PRC2-mediated gene silencing and has been shown to evict Polycomb factors from chromatin 148, 149 . SWI/SNF inactivation is synthetic lethal with EZH2 mutations in a range of cancers. Although SWI/ SNF gene mutations are proposed to drive transformation through gain of PRC2 function and silencing of tumour suppressor genes, non-catalytic activity of EZH2 has also been implicated in tumorigenesis, and it has been suggested that combined loss of SWI/SNF and PRC2 functions could induce cell death due to global transcriptional deregulation rather than derepression of specific PRC2 targets 139, 145, 147, 150 . BAP1 is a deubiquitylating enzyme that targets ubiquitylated H2AK119 and thereby opposes Polycomb-mediated gene silencing 151 ; however, sensitization to EZH2 inhibitors following BAP1 loss appears to be cell type specific and has been observed in mesothelioma but not uveal melanoma 144, 152 . PRC2 can also function as a tumour suppressor, and recurrent inactivating mutations in EZH2 have been reported in myelodysplastic syndrome and chronic myeloproliferative neoplasms [153] [154] [155] [156] [157] . Lossof-function mutations in the genes that encode other core PRC2 components EED and SUZ12 are also seen in T cell acute lymphoblastic leukaemia and malignant peripheral nerve sheath tumours [158] [159] [160] . The contrasting function of PRC2 in different tumour contexts is thought to reflect the crucial roles the specific cellular transcriptional programme and chromatin environment have in determining the genes targeted by PRC2, and highlights the need for careful monitoring of patients treated with EZH2 inhibitors 161 . Aberrant EZH2 activation is a feature of multiple cancers, including breast cancer, castration-resistant prostate cancer, small-cell lung cancer (SCLC) and neuroblastoma, and has been linked to oncogenesis and acquisition of stem cell-like transcriptional programmes [162] [163] [164] [165] [166] [167] [168] . Although upregulation of EZH2 may be a consequence rather than a driver of the malignant process in some cancers 139 , preclinical studies have nevertheless demonstrated that depletion or inhibition of EZH2 impairs proliferation and tumour growth in vivo in many of these tumour types. Multiple EZH2 inhibitors are currently being evaluated in ongoing phase I/II clinical trials in a range of cancers (TAble 1) . Interim phase I trial results have demonstrated a favourable safety and tolerability profile, with dose-limiting toxic effects being a rare occurrence [169] [170] [171] . Encouragingly, in follicular lymphoma, 71% of patients with activating EZH2 SET domain mutations responded to EPZ-6438 (tazemetostat) and 11% of patients achieved a complete response 171 . By contrast, only 33% of the patients without EZH2 mutations responded and 31% developed progressive disease. Promising clinical results have also been reported in BAP1-inactivated malignant mesothelioma, with 51% of patients achieving disease control at 12 weeks, which was sustained to 24 weeks in 25% of the cases 170 . Clinical responses have also been reported in a small number of patients with SMARCB1-mutant tumours 169 . Overall, given that most of the trials were conducted in heavily pretreated patients who had limited treatment options, the responses to EZH2 inhibitors have been encouraging. The increased response rates in tumours with EZH2-activating mutations mirrors preclinical studies and highlights the importance of understanding the mechanisms underlying tumour EZH2 dependence so as to target treatment to those patients most likely to respond 140, [172] [173] [174] . This is particularly important given the highly context-dependent function of EZH2, underscored by the contrasting oncogenic and tumour-suppressive roles of EZH2 in different cancers 161 .
Other inhibitors. DOT1L is an H3K79 methyltransferase that is integral to the initiation and maintenance of leukaemias with recurrent chromosomal translocations involving the mixed-lineage leukaemia gene (MLL, also known as KMT2A, which itself encodes an H3K4 methyltransferase) with other proteins. In a recently reported phase I study, the DOT1L inhibitor EPZ-5676 (pinometostat) (TAble 1) was well tolerated and induced complete remission in 2 of 51 patients with MLL fusion protein leukaemia, providing proof of concept that targeting DOT1L can affect the progression of this aggressive disease 175 . However, the response rates were lower than had been hoped given the crucial role of DOT1L in preclinical models of MLL-fusion-driven malignancies. More recently, the arginine methyltransferase PRMT5 was implicated in driving neoplastic growth of various tumours, including B cell lymphoma, multiple myeloma, breast cancer and glioblastoma [176] [177] [178] [179] [180] [181] [182] [183] . Preclinical studies using PRMT5 inhibition provided a rationale for targeting this enzyme in both haematological and solid tumours, and on the basis of these data, specific inhibitors of PRMT5 recently entered early-stage clinical trials 184 . It is currently too early to know in what cancers these drugs will have the greatest efficacy and whether biomarkers of response may emerge from the clinical evaluation.
Similarly to the context-dependent function of histone methyltransferases, the dynamic association of lysine demethylases with multiprotein complexes governs their stability and substrate specificity 185 . Given its role in promoting cell growth and inhibiting differentiation in AML and SCLC, lysine-specific demethylase 1A (LSD1) has been the primary pharmacological target in the clinical setting to date 137 . Small-molecule inhibitors of LSD1, currently in clinical trials (TAble 1) , irreversibly inhibit its demethylase activity by covalently binding a cofactor. Preliminary results from a phase I trial of ORY-1001 demonstrated an acceptable safety profile and some evidence of clinical efficacy in AML, with partial responses in 3 of 14 patients 186 . Further results are expected from ongoing trials in AML, MDS and SCLC.
Perspective on early clinical trials
Given the unprecedented recent interest in chromatin regulators as cancer therapeutic targets, we now have a suite of small-molecule inhibitors regulating DNA and histone methylation; however, a key challenge is that our preclinical evaluation of these compounds has not translated well to success of these therapies in the clinical arena. Many of the drugs discussed earlier, such as DOT1L, LSD1 and EZH2 inhibitors, showed remarkable promise in preclinical studies but their clinical efficacy has been more modest. What does this mean for future efforts? Far from being unproductive, the clinical studies conducted thus far have been invaluable in highlighting several important points. Overall, epigenetic therapies are safe and tolerable; when assessing inhibitors of ubiquitously expressed proteins, the importance of this finding should not be underestimated. Epigenetic regulators are not directly involved in cell cycle progression or apoptosis, and consequently most of these therapies do not have an immediate cytotoxic effect. Tumour lysis syndrome has rarely been observed when these inhibitors have been used, and most of these drugs have their best clinical response after weeks to months of continuous therapy. Finally, a key lesson learnt is that the value of a specific epigenetic therapy, much like the function of most epigenetic regulators, will be disease specific and context dependent, which explains the relatively low complete response rates in most epigenetic therapy trials.
Given the modest outcomes from the early clinical trials, can we conclude that epigenetic therapies are ineffective? One could argue that anyone who had expected a single-agent epigenetic therapy to be a panacea for multiply relapsed and refractory cancer had not fully appreciated the primary function of this class of proteins and/or the vast adaptive potential of cancer cells. In a way it is not surprising that single-agent epigenetic therapies have had only a modest response in the clinical setting. In somatic tissues, epigenetic regulators function primarily to subtly alter access to the DNA template for DNA repair and replication and for gene expression. The aim for many of these drugs had been to target an essential dependency required to sustain a malignant transcriptional programme. However, targeting epigenetic regulators inevitably induces global changes in chromatin architecture and the cellular transcriptional programme; therefore, the ability to link therapeutic effects with the regulation of specific genes in different tumours is likely to be the exception rather than the rule. It is also important to appreciate that many of the enzymes targeted, particularly lysine and arginine methyltransferases, have non-histone substrates, and the significance of this for the therapeutic and toxic effects of targeting these enzymes is yet to be fully elucidated 187, 188 . It is too early to pass judgement on the role of epigenetic therapies in cancer management. There remains much to be learnt about how best to leverage these small molecules in the clinical setting, and a better understanding of mechanisms of resistance to these drugs is needed. A consistent theme is that cancer cells adapt to survive the therapeutic challenge by finding an alternative mechanism to sustain the malignant gene expression programme in the presence of the epigenetic therapy.
For example, although several epigenetic thera pies targeting the prototypical oncogene MYC through transcriptional repression generated much excitement, it is now clear that this is only transiently effective as cancer cells evolve multiple adaptive responses to retain MYC expression [189] [190] [191] . The mechanisms that underpin these adaptive responses and render epigenetic therapies ineffective are varied and include tumour-intrinsic mechanisms and heterogeneous cellular and molecular effects of the drugs 192 . Thus far the tumour-intrinsic mechanisms of resistance appear to be quite different from the paradigm of acquired resistance reported for other targeted therapies, such as kinase inhibitors 193 . For example, there have been few descriptions of classic gatekeeper mutations in the epigenetic writer, reader and eraser domains targeted by epigenetic drugs. These observations suggest that mutations in the functional domain most likely result in sufficient functional compromise to the epigenetic regulator and probably phenocopy the effects of the drug, consequentially providing no selective advantage to the cancer cell. Preclinical modelling of resistance mechanisms has shown that resistance to these therapies largely emerges through cellular reprogramming and transcriptional plasticity [189] [190] [191] . The possibility that epigenetic therapies provide a fixed barrier that enforces an adaptive transcriptional response from cancer cells presents a unique opportunity. Could epigenetic therapies be used to homogenize intratumour heterogeneity? If the choices of cancer cell adaptation to any therapy are thought of as a large roundabout with several different exits representing alternative routes to adaptation, including genetic evolution, divergent transcriptional programmes or metabolic pathways, or a phenotypic switch such as epithelial-to-mesenchymal transition, could epigenetic therapies be used as an instructive pressure to enforce a homogeneous path to escape? If so, this would create a predictable vulnerability that could be targeted with a second drug in combination to achieve maximum therapeutic benefit. It is likely that the adaptive response to the same epigenetic therapy will be different in a cell context-dependent manner. For this strategy to be effective, a more detailed understanding of the shared routes of escape in each cancer will be required.
Combination and future therapies
The cornerstone of cancer therapy, including the future success of epigenetic therapies, is the use of effective and rational drug combinations. The key issue is how best to combine epigenetic drugs and with what types of other therapies.
Different combination strategies are currently being pursued in clinical trials, including combination of epigenetic therapies with chemotherapy, with targeted therapies and with immunotherapy ( Fig. 4; TAble 1 ). The evidence that cancer cells can escape from selective pressure through transcriptional adaptation provides a molecular rationale for using epigenetic therapy to block or reverse resistance. Furthermore, the potential for epigenetic inhibitors to promote tumour immunogenicity has generated excitement about combining these drugs with immunotherapy, particularly with antibodies 
Gatekeeper mutations
Mutations in the functional domain of a protein that confer resistance to a pharmacological agent while preserving the function of the protein.
targeting T cell inhibitory receptors, such as anti-PD1 and anti-CTLA4 (TAble 1) . The power of such therapies, which are based on immune-checkpoint inhibitors, to induce sustained remission in patients with advanced malignancies has created hope that identifying appropriate complementary therapies will broaden the therapeutic efficacy to encompass more patients and a broader range of tumour types.
Immunotherapy
Common epigenetic regulators govern both inflammationinduced and oncogenic transcriptional programmes 194 . This is particularly relevant to interactions between tumour and host where in an ideal scenario, targeting the same chromatin regulator would inactivate an oncogenic pathway, enhance tumour immunogenicity and modify transcriptional programmes in responding immune cells to enhance their antitumour function. Modulating the host immune response may increase the potency of epigenetic therapies; conversely, a mechanism of function that involves an immune response could in part account for the slow temporal kinetics of epigenetic inhibitors 195 . DNMT and LSD1 inhibitors both induce derepression of endo genous retroviruses and production of double-stranded RNA, which activates antiviral sensing pathways that trigger tumour type I interferon production [196] [197] [198] (Fig. 4) . This enhanced tumour interferon signalling is further augmented following a combination of DNMT inhibitors and histone deacetylase (HDAC) inhibitors, and in preclinical studies these epigenetic drugs induced intratumoural T cell infiltration and augmented the response to immune-checkpoint inhibitors 199, 200 . Chromatin modi fiers also have direct context-dependent roles in shaping cytokine responses and orchestrating immune cell differentiation. For example, inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immuno genicity and the function of infiltrating T cells, natu ral killer cells and macrophages 201 ( Fig. 4) . A role for RNA methylation in modulating immune function was recently reported. Depletion of YTH m 6 A-binding protein 1 (YTHDF1), which binds m 6 A-modified mRNA, enhanced crosspresentation of tumour antigens by dendritic cells. This effect was attributed to inhibition of lysosomal protease production and resulted in substantially enhanced CD8 + T cell-mediated antitumour immunity in Ythdf1-knockout mice 202 .
Targeted therapies
An example of synergism of therapies is provided by the combination of EZH2 inhibition and therapeutic targeting of essential B cell dependencies, as high EZH2 activity has a key role in the pathogenesis of germinal-centre DLBCL and follicular lymphoma through repression of B cell terminal differentiation genes 140 . EZH2 inhibition in both EZH2-mutant and wild type DLBCLs increases their dependence on B cell activation signalling and thus synergizes with inhibitors of B cell receptor signalling such as Bruton's tyrosine kinase inhibitors 203 . The proteins B cell lymphoma 6 (BCL-6) and EZH2 cooperate to maintain stable silencing of B cell differentiation genes and, in preclinical models, combination therapy using E2H2 inhibitors and BCL-6 inhibitors more potently inhibits DLBCL growth than single-agent treatment 204 . Translocations involving BCL-2 are the key driver of follicular lymphoma, and BCL-2 is frequently deregulated in DLBCL. The antiapoptotic function of BCL-2 promotes tumour survival, and BCL-2 inhibitors are currently being evaluated in clinical trials. Combining EZH2 inhibitors with BCL-2 inhibitors more effectively suppresses the growth of DLBCL xenografts 140 .
Chemotherapy
An attractive therapeutic prospect combines chemotherapy with epigenetic drugs that could revert chemoresistant transcriptional programmes 131, 165, 205 . A less explored aspect of such a combination is the potential to use epigenetic drugs to augment cytotoxicity by amplifying the DNA-damaging effects of chemo therapy, + T cells, which secrete the pro-inflammatory cytokines tumour necrosis factor (not shown) and interferon-γ and recognize and kill tumour cells that display foreign antigens in complex with MHC class I (MHC-I). DNMTi, LSD1i and EZH2i can derepress the expression of endogenous retroviruses (ERVs), leading to activation of cellular antiviral RNA sensing pathways and to the production of tumour type I interferon (interferon-α), which acts in an autocrine manner to drive expression of interferon-stimulated genes (ISGs) [196] [197] [198] 231 . Enhanced tumour MHC-I-antigen presentation in conjunction with increased production of the interferon-inducible pro-inflammatory chemokines CXCL9 and CXCL10 augments infiltration of tumours by CD8
+ cytotoxic T cells and tumour killing [232] [233] [234] . DNMT inhibitors can induce aberrant expression of tumour-associated antigens such as cancer testis antigens, which provide a source of 'foreign' MHC-I peptides that may promote the development of tumour-reactive T cells. Manipulation of DNA methylation and histone methylation also modulates the differentiation and function of tumour-infiltrating immune cells, including T cells, natural killer (NK) cells and myeloid cells. Inhibiting EZH2 in regulatory T (T reg ) cells can reprogramme them to become more pro-inflammatory and to enhance the antitumour effects of anti-CTL A4 therapy 235, 236 . DC, dendritic cell; dsRNA , double-stranded RNA ; IFNAR , interferon-α receptor (type I interferon); IFNGR , interferon-γ receptor (type II interferon).
Immune-checkpoint inhibitors
Drugs that target key inhibitory molecules of immune cell activation.
www.nature.com/nrm 584 | oCToBeR 2019 | volume 20 radiotherapy or targeted drugs. DNA and histone methyl ation have a crucial role in the DNA damage response. For example, p53-binding protein 1 (53BP1) is recruited to the site of DNA double-strand breaks and binds to specific post-translationally modified histone residues, including H4K20me2 and H3K79me through its tandem Tudor domain 35, 206 . Blocking H3K79 methylation by depletion of DOT1L inhibits 53BP1 recruitment to double-strand breaks 207 . In yeast, Dot1 promotes DNA repair through homologous recombination, and in mammalian cells DOT1L depletion leads to defects in DNA repair and to enhanced cellular sensitivity to DNAdamaging agents 208, 209 , and also impairs transcriptional recovery following genotoxic stress 210 . Using inhibitors of DOT1L or other epigenetic drugs to sensitize cancer cells to DNA-damaging agents is an important potential therapeutic avenue.
Combining epigenetic therapies
Combinations of two different epigenetic drugs are also being explored in clinical trials, for example those combining DNMT inhibitors with HDAC inhibitors, which have yielded mixed results at the cost of increased toxicity, likely attributable to the broad specificities of the drugs in current clinical use 211 . Given that epigenetic proteins participate in different chromatin complexes with diverse functions, an important limitation of epigenetic therapies is the broad inhibition of all complexes containing the target protein, potentially generating unwanted adverse effects. An innovative strategy to more selectively target a specific epigenetic regulatory complex is the development of inhibitors that concurrently target two proteins within the same complex. The feasibility of this approach was demonstrated by the recent development of dual inhibitors of LSD1 and HDACs, which provide more effective and sustained inhibition of the REST co-repressor 1 complex than existing class I HDAC inhibitors, and more potently inhibit melanoma proliferation while being less toxic to normal melanocytes and keratinocytes 212 . Given the ongoing development and rapid expansion of a library of molecules that bind to specific reader, writer and eraser domains, the prospect of taking an epigenetic complex-focused approach to the development of targeted therapeutics becomes more tangible and should allow more refined targeting of a specific deregulated process, while limiting off-target effects.
Emerging clinical prospects
The observations that derepression of endogenous retroviruses can enhance anticancer immune surveillance through viral mimicry highlight the potential of specifically leveraging genomic repeats for therapeutic gain (boX 1). Another emerging area of research with boundless opportunities is the possibility of repurposing sequence-specific genome editing strategies as therapeutic agents. The feasibility of specifically directing components of the DNA or histone methylation machineries for gene-specific regulation in human cells has been established ex vivo 213 . Similarly, epigenetic therapies can also be targeted to specific genomic loci using CRISPR-Cas-associated protein tools coupled to therapeutic compounds 214 ( Fig. 5a ). These tools may allow us to effectively activate or silence specific genes or large stretches of chromatin, and to specifically alter chromatin topology, replication timing and DNA repair. The application of these tools in preclinical models is yet to be explored, and transitioning to clinical approaches will require considerable innovation. However, with future advances in medicinal chemistry coupled with novel delivery modalities, these strategies may soon enable us to apply precision medicine.
The nonrandom nature of methylome profiles also suggests a common mechanism of development or a common cell of origin for distinct tumour subtypes. Consistent with this, genome-wide mapping of DNA methylation changes has proved useful for classification of cancer into prognostic subgroups 100, 107 and for the development of clinically applicable assays in AML 215 . DNA methylation also has several advantages as a biomarker for cancer diagnosis, including early and frequent occurrence of DNA methylation changes in cancer and cell-type specificity. DNA methylation is stable in fixed samples and can be easily detected in a range of bodily fluids by well-established techniques (Fig. 5b) . Despite this, publication of almost 200 biomarkers has yielded only 14 commercially available DNA methylation-based biomarker assays designed to measure the methylation of only 13 genes (for a recent review, see reF.
216
), and only one of these is used to guide treatment decisions 217 . There is currently great interest in developing non-invasive methods to monitor dynamic changes in mutation status and DNA methylation for diagnosis and prognosis. The potential clinical application of this approach was recently shown for profiling the methylation of cell-free tumour DNA circulating in plasma 218 . Similarly, changes in genomic 5hmC profiles can also be broadly used as a diagnostic biomarker for cancers, and the development of protocols for detecting 5hmC is of great interest.
Box 1 | Exploiting the non-coding genome for therapy
Transposable elements constitute the largest fraction of the human genome, and methylation of DNA and histones has an integral role in their regulation. Although evolutionarily diverse, these elements have a fundamental role in development and disease 221 . Transposons can be highly cell-lineage specific and can regulate tissue gene expression programmes through mechanisms involving the active promotion or repression of transcription. Transposable elements have been proposed to be critical for establishing the chromatin environment that facilitates cellular plasticity, a feature not only required for normal development but that is often a central component of oncogenesis 221 . In some tissues up to 30% of transcripts could originate from repetitive elements, highlighting their influence on tissue-specific gene expression 222 . many transposable elements have a conserved regulatory structure, such as long terminal repeats, which provide a promoter at the 5′ end and transcription termination and polyadenylation signals at the 3′ end of some retrotransposons. Consequently, evolutionary pressure has likely evolved distinct mechanisms, including epigenetic mechanisms to tightly control the genomic effects of transposons. An example of epigenetic control of the expression (and activity) of transposable elements is the vertebrate-specific chromatin-modifying complex human silencing hub (HuSH), which regulates the long interspersed nuclear element 1 family of retrotransposons 223, 224 . Some of these transposon families may be amenable to therapeutic manipulation with epigenetic drugs to effectively manage diseases such as cancer. 
Conclusions and future perspective
The past decade has seen a great convergence of what were previously largely disparate fields of research in genomics, epigenetics and chemistry. The great genomic efforts to document all the recurrent mutations that underpin various developmental disorders and cancers have reinforced the central role of chromatin regulators in the cause of these diseases. Concurrently, decades of careful chromatin investigation using chemical, cell and molecular bio logy have provided invaluable insights into the molecular function of these epigenetic regulators. These insights have highlighted the highly dynamic nature of the epi genome and provided the molecular rationale for therapeutically targeting these proteins. This challenge has been widely embraced by medicinal chemists in academia and in the pharmaceutical industry. Together, they have produced an unprecedented array of small molecules that target proteins responsible for writing, reading or erasing methylation of DNA and histone proteins. Several of these epigenetic therapies have rapidly progressed to early-phase clinical trials, which have been invaluable in establishing the safety of many of these compounds and demonstrate that even as single agents in relapsed and refractory cancers they show efficacy.
The platform for cross-disciplinary progress has now been established. It provides a unique oppor tunity to make dramatic inroads into the understanding and management of various human diseases. The success of this ambition rests on how we tackle the next frontier of challenges. Here we see several opportunities: our understanding of the non-coding genome, particularly of transposable elements, is still rudimentary. Investigating the regulation of the largest fraction of our genome and the role it has in normal development and pathological processes such as cancer may yield new opportunities for therapeutic intervention. Another opportunity lies in finding innovative methods to use the knowledge gained over the past decade to guide diagnosis and management in everyday clinical practice. Recent efforts to use the highly annotated cancer genome to monitor response and resistance to cancer therapies 219, 220 raise the possibility that cancer-specific DNA and RNA modifications may similarly prove effective. Finally, arguably the most important opportunity is identifying how best to integrate epigenetic therapies into routine clinical management. The future clearly involves combination strategies; however, given the context-dependent function of epigenetic regulators, it is important to carefully establish the best evidence for combination drug regimens involving an epigenetic therapy. This is not an insignificant task as all animal models of cancer have significant limitations. Genetically engineered mouse models fail to recapitulate the intratumour hetero geneity inherent in human cancer, and patient-derived xenograft models also have major limitations in clonal representation and lack an effective immune system, which, as discussed earlier, appears to be central to the efficacy of many epigenetic therapies. Therefore, it is important to acknowledge and accept these limitations and not be guided solely by preclinical evidence in imperfect animal models of cancer. A detailed understanding of the molecular mechanism that may provide therapeutic benefit may be equally, if not more, valu able than empirical preclinical efficacy studies. Despite these challenges, there is much to be optimistic about in the future of epigenetic therapies. The multidisciplinary collaborative approach in recent years involving geneticists, biochemists, medicinal chemists, cell bio logists and clinicians has yielded an enormous amount of knowledge about the fundamental role of epigenetic regulators in diseases associated with advanced age, including cancer. Continued collaborative efforts will likely make significant inroads into altering the natural history of these disorders soon. 
